MC2 Therapeutics
MC2 Therapeutics is a private Danish specialty pharmaceutical company that develops topical therapies for inflammatory skin conditions using its proprietary PAD Technology™ platform, commercializing Wynzora® Cream for plaque psoriasis through regional licensing partners across 40+ countries and four continents.
- Company typePrivate
- Founded2011
- HeadquartersHørsholm, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What MC2 Therapeutics does
MC2 Therapeutics A/S is a private specialty pharmaceutical company headquartered in Hørsholm, Denmark, founded in 2011 (originally as MC2 Biotek and renamed in December 2016) and controlled by founding majority owner Mads Clausen. The company develops topical therapies for inflammatory skin conditions based on its proprietary PAD Technology™ platform—a formulation and drug delivery system that enables oil-in-water cream formulations with high penetration, solubility, and stability of active ingredients using only a fraction of the emulsifiers required by conventional creams. Its commercialized product, Wynzora® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%), received FDA approval in July 2020 for plaque psoriasis, with subsequent EU decentralized procedure approval (first country July 2021), Australian TGA approval (November 2024), and Health Canada approval (November 2025); Phase III dosing in China began in January 2026. The pipeline includes MC2-25 (a first-in-class carbamylation inhibitor for CKD-associated pruritus and Vulvar Lichen Sclerosus), MC2-32 (an oral HSP90 inhibitor option-licensed from Regranion for Hidradenitis Suppurativa), MC2-03 (ciclosporin 0.06% ophthalmic formulation for dry eye disease), and the Biomee® dermo-cosmetics line.
The company operates a pure out-licensing business model: it retains product ownership, manufacturing, and supply responsibility while granting exclusive regional commercialization rights to established pharmaceutical partners in exchange for upfront payments, regulatory and sales milestone payments, and tiered double-digit royalties. Current licensees are EPI Health (US), Almirall (Europe, EUR 15M upfront in February 2021), Huadong Medicine (Greater China, USD 16M upfront plus USD 36M milestones in August 2023, expanded December 2025 to include Biomee®), Knight Therapeutics (Canada, Health Canada approval November 2025), Hyphens Pharma (ASEAN), and Actor Pharmaceuticals (Australia, TGA approval November 2024), collectively covering more than 40 countries across four continents. With 11–50 employees and wholly owned subsidiaries in the UK (Guildford) and US, MC2 serves dermatology patients (plaque psoriasis), nephrology/dialysis patients (CKD-aP), and underserved indications (VLS, HS) where few or no approved therapies exist, leveraging a leadership team with deep dermatology R&D and Big Pharma commercial credentials.
MC2 Therapeutics firmographics
Firmographics- Name
- MC2 Therapeutics
- Legal name
- MC2 Therapeutics A/S
- Website
- https://mc2therapeutics.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MC2 Therapeutics is a private Danish specialty pharmaceutical company that develops topical therapies for inflammatory skin conditions using its proprietary PAD Technology™ platform, commercializing Wynzora® Cream for plaque psoriasis through regional licensing partners across 40+ countries and four continents.
- Ownership category
- akta.pro rank
MC2 Therapeutics industry classification
Industry- Product category
- Topical dermatology pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
- akta.pro secondary industries
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Treatment Skincare (Serums, Actives, Acne & Anti-aging) (CRABAAAB), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)
Keywords
Where MC2 Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Hørsholm
- HQ country
- Denmark
- HQ region
- Europe
Offices2 records
Markets served
MC2 Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Product Licensing and Royalties: MC2 Therapeutics licenses its commercialized products (Wynzora® Cream) to regional pharmaceutical partners in exchange for upfront payments, regulatory milestones, sales milestones, and tiered double-digit royalties. The company retains manufacturing and supply responsibilities while partners handle commercialization in their territories.
- Dermo-cosmetic Product Sales: The company manufactures and supplies its Biomee® dermo-cosmetic cream products (Biomee® Itch and Biomee® Dry Skin) to partners like Huadong for commercialization in their regions.
Go-to-market motion1 record
Distribution channels6 records
Marketing channels3 records
MC2 Therapeutics product offering
Product offeringCore offering
MC2 Therapeutics develops, manufactures, and commercializes topical pharmaceutical therapies and dermo-cosmetics for inflammatory skin conditions, leveraging its proprietary PAD Technology™ single-phase aqueous cream platform. Its lead product is Wynzora® Cream, an FDA-approved fixed-dose combination of calcipotriene and betamethasone dipropionate for plaque psoriasis in adults, supplemented by dermo-cosmetic product lines (Biomee® Itch, Biomee® Dry Skin) and a development pipeline covering ophthalmology, uremic pruritus, venous leg ulcers, and chronic kidney disease–associated pruritus.
Product overview
MC2 Therapeutics is a private pharmaceutical company offering a portfolio of topical therapies and dermo-cosmetics for inflammatory skin conditions. The core product is Wynzora® Cream (FDA-approved 2020, EU-approved 2021), a fixed-dose combination of calcipotriene and betamethasone dipropionate for plaque psoriasis enabled by the proprietary PAD Technology™ platform. The company has expanded into dermo-cosmetics with the Biomee® line (Itch and Dry Skin creams), and maintains a pipeline of drug candidates including MC2-25 for CKD-associated pruritus, MC2-25 VLS for Vulvar Lichen Sclerosus, and MC2-32 for Hidradenitis Suppurativa, all leveraging PAD Technology™ or novel mechanisms of action.
Differentiator
Problem solved
Functional benefit
Brands
- Wynzora: Wynzora Cream - a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis. Enabled by PAD Technology.
- Biomee
- PAD Technology
Products and services
- Wynzora® Cream Wynzora® Cream is a fixed-dose combination of calcipotriene and betamethasone dipropionate topical cream developed with PAD Technology™, indicated for the topical treatment of plaque psoriasis in adults 18 years of age and older. It is prescribed by dermatologists and commercialized through regional licensing partners in the U.S., EU, and other markets.
- Biomee® Itch Biomee® Itch is a consumer dermo-cosmetic skincare product in MC2's Biomee® line, formulated to address skin itching and irritation, leveraging the company's dermatology formulation expertise.
- Biomee® Dry Skin Biomee® Dry Skin is a consumer dermo-cosmetic skincare product in MC2's Biomee® line, formulated to moisturize and care for dry skin, leveraging the company's dermatology formulation expertise.
- MC2-03 PAD Eye Drop MC2-03 PAD Eye Drop is an ophthalmic product developed with PAD Technology™, initially launched in the United Kingdom in 2012 as a Special product, representing one of MC2's first commercial applications of its topical delivery platform.
Quantifiable outcome
- PGA treatment success: 40.1% vs 24.0% for comparator (Taclonex®) in Phase 3 psoriasis trial
- +3 more outcomes
Companies that use MC2 Therapeutics
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
MC2 Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
MC2 Therapeutics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered major, core and minor.
- Actor Pharmaceuticals Pty LtdmajorAgreement granting exclusive rights to commercialize Wynzora® Cream for treatment of plaque psoriasis in Australia. Wynzora® Cream was approved by TGA in November 2024 for topical treatment of mild to moderate plaque psoriasis on the body and scalp psoriasis in adults.
- Knight Therapeutics Inc.majorLicense and commercialization agreement for Wynzora® Cream in Canada. Knight Therapeutics obtained Health Canada approval in November 2025 for topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks.
- Hyphens Pharma Pte. Ltd.majorLicense, supply and commercialization agreement for Wynzora® Cream in ASEAN countries.
- Regranion, LLCcoreOption to exclusively license RGRN-305 (now MC2-32) for all human indications globally, excluding Greater China. RGRN-305 is an orally administered HSP90 inhibitor for Hidradenitis Suppurativa and other immune-mediated inflammatory diseases. MC2 acquired global option rights in September 2023.
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong)coreLicense, development and commercialization agreement for Wynzora® Cream in Greater China (mainland China, Hong Kong, Macau, Taiwan). MC2 received USD 16 million upfront and is eligible for USD 36 million in sales milestones plus tiered double-digit royalties. Huadong is responsible for development and commercialization with oversight from a joint steering committee. In December 2025, the partnership expanded to include Biomee® Itch and Biomee® Dry Skin dermo-cosmetic products.
- Almirall S.A.coreLicense, collaboration and commercialization agreement for European rights to Wynzora® Cream. MC2 received EUR 15 million upfront plus launch payments and is eligible for significant sales milestone payments and double-digit royalties. Almirall commercializes Wynzora® Cream in Europe while MC2 maintains responsibility for manufacturing and supply.
- EPI Health, LLCcoreCollaboration agreement for US commercialization of WYNZORA® Cream. MC2 retains full ownership of the product. EPI Health utilizes its commercial infrastructure to promote and sell WYNZORA® Cream in return for a share of net sales.
- Moorfields PharmaceuticalsminorCollaboration and license agreement for development of novel ophthalmic products based on PAD Technology. Moorfields obtained exclusive rights to develop ophthalmic 'Specials' (unlicensed medicinal products) in UK and Ireland, while MC2 retained rights to develop licensed ophthalmic products.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
MC2 Therapeutics competitors and assessment
Company assessmentDirect peers
- LEO Pharma: Privately-held Danish specialty dermatology pharma with a leading psoriasis franchise (e.g., Enstilar®, Taclonex®/Dovobet®, Adtralza®). Directly comparable to MC2 as a European-headquartered dermatology-focused company commercializing topical and systemic psoriasis therapies.
- Maruho Co., Ltd. Japan-based specialty dermatology pharmaceutical company with topical franchises for psoriasis and atopic dermatitis. Comparable as a regional specialty dermatology player leveraging topical formulation expertise.
- Arcutis Biotherapeutics: US specialty dermatology company commercializing topical therapies for psoriasis (Zoryve® cream/foam) and atopic dermatitis. Direct peer as a small-cap, dermatology-focused company leveraging novel topical drug delivery and partnerships for global commercialization.
- Dermavant Sciences: Roivant-affiliated dermatology company that developed Vtama® (tapinarof) for psoriasis and atopic dermatitis. Direct peer in the topical psoriasis space with comparable Phase 3-driven, partner-supported commercialization strategy.
- Anacor Pharmaceuticals: Historical comp: small US dermatology-focused pharma acquired by Pfizer in 2016 for ~$5.2B. Closely comparable to MC2 in size, structure, and dermatology innovation model. (Acquirer Pfizer listed separately as broad incumbent.)
Emerging players
- UCB: Belgian pharma with Cimzia® approved for Hidradenitis Suppurativa, directly competing with MC2-32. Emerging player overlap in the HS indication, with broader inflammation/immunology franchise.
Broad incumbents
- Pfizer: Global pharma with dermatology presence following the Anacor acquisition. Also a potential strategic acquirer comparable in scale to typical MC2 exit paths; competes in inflammatory skin disease pipeline.
- AbbVie: Global pharma with major dermatology franchise including Humira® (psoriasis), Skyrizi® (psoriasis), and Rinvoq® (atopic dermatitis). Broad incumbent competing against MC2's Wynzora® via newer IL-23 and JAK inhibitor franchises.
- Galderma: Global dermatology-focused company across prescription (e.g., Epiduo®, Differin®, Soolantra®), aesthetics, and dermo-cosmetics. Broad incumbent comparable to MC2 across both prescription dermatology (Wynzora®) and dermo-cosmetic (Biomee®) lines.
- Incyte Corporation: Commercializes Opzelura® (ruxolitinib cream), a leading non-steroidal topical in atopic dermatitis and vitiligo. Broad incumbent overlapping with MC2's dermatology/topical focus, with substantially larger commercial resources.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
MC2 Therapeutics social profiles
Digital presenceMC2 Therapeutics compliance and trust
Trust signalCompliance1 record
MC2 Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MC2 Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
MC2 Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
MC2 Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MC2 Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MC2 Therapeutics
What does MC2 Therapeutics do?
MC2 Therapeutics develops, manufactures, and commercializes topical pharmaceutical therapies and dermo-cosmetics for inflammatory skin conditions, leveraging its proprietary PAD Technology™ single-phase aqueous cream platform. Its lead product is Wynzora® Cream, an FDA-approved fixed-dose combination of calcipotriene and betamethasone dipropionate for plaque psoriasis in adults, supplemented by dermo-cosmetic product lines (Biomee® Itch, Biomee® Dry Skin) and a development pipeline covering ophthalmology, uremic pruritus, venous leg ulcers, and chronic kidney disease–associated pruritus.
Is MC2 Therapeutics a public or private company?
MC2 Therapeutics is a private company. It is classified as family owned and is currently operating.
When was MC2 Therapeutics founded?
MC2 Therapeutics was founded in 2011. It employs 11 to 50 people.
Where is MC2 Therapeutics based?
MC2 Therapeutics is headquartered in Hørsholm, Denmark, in the Europe region.
How does MC2 Therapeutics make money?
Two revenue lines are on record. Product Licensing and Royalties are the primary driver. The others are dermo-cosmetic Product Sales.
Who are MC2 Therapeutics's main competitors?
Direct peers on record are LEO Pharma, Maruho Co., Ltd., Arcutis Biotherapeutics, Dermavant Sciences and Anacor Pharmaceuticals. UCB is listed as an emerging player. Broad incumbents are Pfizer, AbbVie, Galderma and Incyte Corporation.
Does MC2 Therapeutics have an API?
No public API is recorded for MC2 Therapeutics.
What industry is MC2 Therapeutics in?
MC2 Therapeutics's product category is Topical dermatology pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2844.